AI Revolutionizes Vaccine Development at Siena Biotecnopole Foundation
Siena, Italy – March 17, 2026 – A new era in vaccine development is underway at the Biotechnopole Foundation of Siena, where researchers are leveraging the power of artificial intelligence to identify potential vaccination targets with unprecedented speed and precision. Building on decades of advancements in reverse vaccinology, this latest innovation promises to dramatically accelerate the response to emerging infectious diseases and future pandemics.
The Evolution of Reverse Vaccinology
The foundation’s operate builds upon the principles of reverse vaccinology, a technique pioneered in the early 2000s by Rino Rappuoli and first applied to the study of meningococcus B. Traditionally, vaccines were developed by growing and studying viruses and bacteria in the laboratory. Reverse vaccinology, however, shifted the focus to analyzing the genome of the pathogen to identify protective antigens – the parts of the virus or bacteria that the immune system recognizes and attacks – from which a vaccine could then be developed.
This approach evolved into “reverse Vaccinology 2.0,” which incorporated the study of human monoclonal antibodies, capable of neutralizing viruses. This allowed researchers to pinpoint the specific parts of a pathogen responsible for immune protection, leading to more effective vaccine targets.
Reverse Vaccinology 3.0: The AI Leap
The current breakthrough, dubbed “reverse Vaccinology 3.0,” integrates genomics, human immunology, structural biology, and artificial intelligence. “Artificial intelligence allows us to analyze large quantities of biological data – explains Rino Rappuoli – and to identify new vaccination targets in times that were unthinkable until a few years ago,” according to a press release from the foundation.
Researchers can now analyze data on antibodies and antigens using advanced computational models, drastically reducing the time needed to identify new vaccine targets. Where it previously could take up to three years to identify antibodies capable of blocking a virus, the new AI-powered approach has achieved this in just five days.
Applications Beyond Vaccines
While initially focused on vaccine development, the integration of biology and AI holds potential for broader applications. Researchers believe the same technologies could be used in the development of anti-tumor immunotherapies and strategies for autoimmune diseases. The Biotechnopole Foundation of Siena aims to be a national hub for preparedness against future epidemic and pandemic risks, contributing to the global fight against emerging pathogens.
Meningococcal Vaccination in Italy
Meningococcus B remains the most common serogroup causing meningococcal disease in Italy, accounting for a significant percentage of cases. According to data from 2011-2013, it was responsible for 46-63% of reported cases. In 2016, vaccination against meningococcal C was available through regional health services in the province of Siena, and in 2014, the Tuscany region announced free vaccination against Meningococco B. Siena News reported on these initiatives.
A doctor advising a couple moving to Siena in 2017 recommended vaccination, noting the availability of free vaccination against the B strain in the Tuscany region. As reported by Medicitalia.it, the doctor suggested vaccination could provide psychological reassurance.
Recent Developments
In November 2019, a three-year-traditional child was hospitalized with a meningococcal B infection at the Meyer Hospital in Florence. Siena News covered this case, highlighting the ongoing relevance of meningococcal disease in the region. In December 2014, Novartis received the Premio Galeno Italia for its vaccine against meningococcal B, developed in its Siena laboratories. Siena News also reported on this recognition.
MSN Italy reported on the advancements in vaccine development using AI on March 17, 2026.